Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:02:35.153Z.
Consensus retrieved: 2026-10-06T12:38:06.741Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:02:35.153Z.
Quote observation: 2026-10-06T18:00:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9c158031491460a86e7ac8af144b753a63209dee503cd84cf8c2ef07d35a683f
Forward PE Ratio (N/A) = Dated Quote Price ($158.47) / Consensus Forward EPS ($8.74)
FORWARD PE RATIO
N/A
ICU Medical, Inc.
Market Cap
$3.96B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ICU Medical, Inc. (ICUI) | $3.96B | N/A |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.00B | N/A |
| AbCellera Biologics Inc. (ABCL)vs › | $4.05B | N/A |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.79B | N/A |
| LivaNova PLC (LIVN)vs › | $4.15B | 17.34 |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.28B | N/A |
| Veracyte, Inc. (VCYT)vs › | $3.55B | 23.26 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.54B | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.41B | 8.38 |
Trailing P/E
134.3
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $8.74 implies +640.7% EPS growth vs the reported trailing $1.18.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
At the dated quote price of $158.47, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $8.74 | $8.70 – $8.80 | 6 | 18.1x |
| 2027-12-31 | $9.67 | $9.45 – $10.05 | 6 | 16.4x |
| 2028-12-31 | $10.40 | $7.08 – $13.25 | 3 | 15.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
